Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) by 12.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 27,668 shares of the biopharmaceutical company’s stock after selling 3,952 shares during the quarter. Calamos Advisors LLC’s holdings in Intra-Cellular Therapies were worth $2,311,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in Intra-Cellular Therapies during the third quarter valued at $32,000. GAMMA Investing LLC raised its position in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $74,000. Wilmington Savings Fund Society FSB acquired a new stake in Intra-Cellular Therapies in the 3rd quarter worth about $97,000. Finally, Quarry LP increased its stake in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Needham & Company LLC reissued a “hold” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $103.62.

View Our Latest Research Report on Intra-Cellular Therapies

Intra-Cellular Therapies Stock Down 0.2 %

ITCI stock opened at $126.90 on Wednesday. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.00. The stock has a market cap of $13.45 billion, a price-to-earnings ratio of -145.86 and a beta of 0.72. The business has a fifty day moving average of $99.10 and a two-hundred day moving average of $85.28.

Insider Buying and Selling

In related news, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Company Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

See Also

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.